• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Candel Therapeutics Inc.

    3/13/25 4:45:53 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CADL alert in real time by email
    S-8 1 d932796ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 13, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    CANDEL THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   52-2214851

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    117 Kendrick St., Suite 450

    Needham, MA

      02494
    (Address of Principal Executive Offices)   (Zip Code)

    Candel Therapeutics, Inc. 2021 Stock Option and Incentive Plan

    Candel Therapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

    Paul Peter Tak, M.D., Ph.D.

    President and Chief Executive Officer

    Candel Therapeutics, Inc.

    117 Kendrick St, Suite 450

    Needham, MA 02494

    (Name and address of agent for service)

    (617) 916-5445

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William D. Collins, Esq.

    Finnbarr D. Murphy, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This registration statement on Form S-8 relating to the 2021 Stock Option and Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“the “2021 ESPP”) (together, the “Plans”) of Candel Therapeutics, Inc. is being filed for the purpose of registering additional securities of the same class as other securities for which a registration statement on Form S-8 relating to the Plans has previously been filed and is effective. Accordingly, pursuant to General Instruction E, the information contained in the registrant’s registration statements on Form S-8 (File Nos. 333-258279, 333-263961, 333-270967 and 333-278294) is hereby incorporated by reference and made a part of this registration statement, except as presented below in Part II, Item 8. Exhibits.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    EXHIBIT INDEX

     

    Exhibit

    No.

       Description
    4.1    Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 30, 2021).
    4.2    Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 30, 2021).
    4.3    Amendment to the Amended and Restated Bylaws of Candel Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 30, 2024).
    4.4    Second Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of KPMG LLP, Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    99.2    2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Needham, State of Massachusetts, on this 13th day of March, 2025.

     

    CANDEL THERAPEUTICS, INC.
    By:  

    /s/ Paul Peter Tak

     

    Name: Paul Peter Tak, M.D., Ph.D.

    Title: President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Paul Peter Tak, M.D., Ph.D. and Charles Schoch, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name    Title    Date

    /s/ Paul Peter Tak

       President, Chief Executive Officer and Director    March 13, 2025
    Paul Peter Tak, M.D., Ph.D.    Principal Executive Officer   

    /s/ Charles Schoch

       Interim Chief Financial Officer    March 13, 2025
    Charles Schoch    Principal Financial Officer and Principal Accounting Officer   

    /s/ Paul B. Manning

       Director    March 13, 2025
    Paul B. Manning

    /s/ Edward J. Benz, Jr.

       Director    March 13, 2025
    Edward J. Benz, Jr., M.D.

    /s/ Renee Gaeta

       Director    March 13, 2025
    Renee Gaeta

    /s/ Nicoletta Loggia

       Director    March 13, 2025
    Nicoletta Loggia

    /s/ Christopher Martell

       Director    March 13, 2025
    Christopher Martell

    /s/ Gary J. Nabel

       Director    March 13, 2025
    Gary J. Nabel, M.D., Ph.D.

    /s/ Diem Nguyen

       Director    March 13, 2025
    Diem Nguyen, Ph.D., M.B.A.

    /s/ Joseph C. Papa

       Director    March 13, 2025
    Joseph C. Papa
    Get the next $CADL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CADL

    DatePrice TargetRatingAnalyst
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    8/23/2021$9.00Buy
    UBS
    8/23/2021$22.00Buy
    Jefferies
    8/23/2021$15.00Outperform
    Credit Suisse
    More analyst ratings

    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Candel Therapeutics with a new price target

      Citigroup initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $25.00

      2/20/25 6:59:49 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Canaccord Genuity initiated coverage on Candel Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $20.00

      2/19/25 7:01:43 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on Candel Therapeutics with a new price target

      BofA Securities initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $15.00

      2/7/25 8:23:12 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      12/18/24 4:11:47 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Candel Therapeutics to Present at Upcoming Investor Conferences

      NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences.                                                  Bank of America Securities 2025 Health Care Conference (Las Vegas, NV)Presenter: Francesca Barone, MD, PhD, Candel's Chief Scientific OfficerDate/Time: Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ETWebcast Link: Bank of America / Candel Presentation Jefferies G

      5/6/25 8:05:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

      NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company's phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer. Details are as follows: CAN-2409 – Localized Prostate Cancer Abstract Title: Phase 3,

      4/23/25 4:05:00 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

      NEEDHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the publication of a manuscript reporting the results of a phase 1b clinical trial exploring safety and tolerability of the combination of CAN-2409 plus prodrug (valacyclovir) and nivolumab, in addition to standard of care (neurosurgery, radiotherapy, and temozolomide), in patients with newly diagnosed high-grade glioma. The study, which includes evidence of clinical activity and extensive biomarker analysis, has been published

      4/1/25 8:01:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Candel Therapeutics Inc.

      DEFA14A - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/29/25 4:08:48 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Candel Therapeutics Inc.

      DEF 14A - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/29/25 4:05:15 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

      4/23/25 4:15:31 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Leadership Updates

    Live Leadership Updates

    See more

    $CADL
    Financials

    Live finance-specific insights

    See more
    • Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

      NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Elizabeth M. Jaffee, M.D., to the Company's Research Advisory Board (RAB). Dr. Jaffee, an internationally recognized expert in cancer immunology and pancreatic cancer, brings her extensive expertise to the RAB, which is important in light of the Company's focus on borderline resectable pancreatic cancer. Dr. Jaffee currently serves as the Dana and Albert "Cubby" Broccoli Professor of Oncology, Deputy Dire

      3/18/25 8:00:46 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Candel Therapeutics to Join Russell 3000® Index

      NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitaliza

      6/11/24 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

      Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients

      12/11/24 7:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

      Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a

      3/30/23 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

      NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. "Candel remains on track to achieve several milestones in the second half of 2022," said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. "We are encouraged by the initial phase 2 clinical trial data for CAN-2409 in non-small cell lung cancer presented in June at ASCO. The data presented at ASCO showed an 87.5

      8/5/22 8:00:00 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      12/17/24 12:30:40 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Candel Therapeutics Inc. (Amendment)

      SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/9/23 9:59:40 AM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Candel Therapeutics Inc.

      SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

      2/14/22 4:40:59 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Barone Francesca exercised 18,000 shares at a strike of $1.55 and sold $281,673 worth of shares (32,146 units at $8.76), decreasing direct ownership by 13% to 96,527 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:36:03 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Nichols William Garrett exercised 18,489 shares at a strike of $1.90 and sold $396,995 worth of shares (45,316 units at $8.76), decreasing direct ownership by 34% to 52,493 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:36:22 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Tak Paul Peter sold $229,624 worth of shares (26,172 units at $8.77), decreasing direct ownership by 10% to 225,740 units (SEC Form 4)

      4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

      3/20/25 4:35:42 PM ET
      $CADL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care